Genexine, Inc. (KOSDAQ:095700)

South Korea · Delayed Price · Currency is KRW

2,140.00

-20.00 (-0.93%)

Nov 2, 2026, 3:30 PM KST

Market Cap	97.33B -58.6%
Revenue (ttm)	5.81B -3.5%
Net Income	-54.53B
EPS	-1,320.62
Shares Out	45.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,261
Open	2,105.00
Previous Close	2,160.00
Day's Range	2,105.00 - 2,185.00
52-Week Range	2,105.00 - 7,490.00
Beta	0.41
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Genexine

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 86

Stock Exchange KOSDAQ

Ticker Symbol 095700

Full Company Profile

Financial Performance

In 2023, Genexine's revenue was 4.43 billion, a decrease of -72.57% compared to the previous year's 16.14 billion. Losses were -66.87 billion, 19.5% more than in 2022.

Financial Statements